John brings more than 40 years of clinical and diagnostic biomarker experience and senior scientific leadership to Immunologix Laboratories. He is responsible for the scientific oversight of all clinical biomarker strategies for biomarker analysis in both preclinical and clinical studies. John is a well recognized industry leader in clinical biomarkers including co-authorship on the first consensus white paper on biomarker assay validation requirements as a Member of the AAPS Ligand Binding Assay Bioanalytical Focus Group (LBABFG) Biomarker Committee. John spent over 20 years in NHS Clinical Pathology services before moving into the CRO industry where he managed the Central Laboratory for Covance before leading the biomarker laboratories at BAS International, Veeda, ICON Laboratories, and LGC Limited. He has authored numerous peer reviewed publications and book chapters on the use of commercial biomarker assays in drug development.